Pluri (NASDAQ:PLUR) Trading Down 1.6% – Here’s What Happened

Pluri Inc. (NASDAQ:PLUR)’s stock price was down 1.6% during mid-day trading on Monday . The company traded as low as $3.01 and last traded at $3.06. Approximately 22,478 shares changed hands during mid-day trading, an increase of 278% from the average daily volume of 5,947 shares. The stock had previously closed at $3.11.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pluri in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $12.00.

Pluri Price Performance

The company’s 50-day moving average price is $3.42 and its 200-day moving average price is $3.70. The company has a market cap of $30.75 million, a P/E ratio of -0.62 and a beta of 0.66.

Pluri (NASDAQ:PLUR) last posted its quarterly earnings data on Thursday, February 12th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.06). The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.64 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC acquired a new position in shares of Pluri Inc. (NASDAQ:PLUR) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.14% of Pluri as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 16.59% of the company’s stock.

Pluri Company Profile

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.